Soligenix Inc. (NASDAQ: SNGX) recently provided an update on the progress of its Phase 3 trial for HyBryte(TM), a novel treatment for cutaneous T-cell lymphoma (CTCL), during an investment webinar. The company highlighted interim results from an investigator-initiated study at the University of Pennsylvania, where 75% of the first eight patients completing 18 weeks of treatment showed a greater than 50% reduction in disease severity. This development is significant as CTCL, a rare non-Hodgkin’s lymphoma, affects a considerable number of patients with limited treatment options available.
HyBryte(TM), Soligenix's lead asset, is a topical therapy activated by visible light, designed to target early-stage mycosis fungoides, which constitutes nearly 90% of CTCL cases. The therapy's mechanism offers a promising alternative to current treatments, which often come with significant side effects. With top-line results from the Phase 3 trial expected in the second half of 2026, the medical community and patients alike are keenly watching for potential advancements in CTCL treatment options.
The webinar, led by Dr. Christopher Schaber and Dr. Christopher Pullion, underscored Soligenix's commitment to addressing rare diseases and unmet medical needs. The positive interim results not only bolster the case for HyBryte(TM)'s efficacy but also highlight the importance of continued investment in rare disease research. For more information on the trial, visit https://ibn.fm/dz7eO.
